November 10, 2022

Press release - Non-regulatory

Hubro Therapeutics AS acquires GM-CSF vaccine adjuvant from Targovax ASA in asset purchase agreement

November 3, 2022

Press release - Regulatory

Targovax ASA: Third quarter 2022 results

October 26, 2022

Press release - Regulatory

Invitation to Targovax’s third quarter 2022 presentation, Thursday 3 November

October 20, 2022

Press release - Non-regulatory

The ONCOS-102 phase 1b melanoma study is published in the prestigious scientific journal Clinical Cancer Research – with updated publication info

October 20, 2022

Press release - Non-regulatory

The ONCOS-102 phase 1b melanoma study is published in the prestigious scientific journal Clinical Cancer Research

October 5, 2022

Press release - Non-regulatory

The ONCOS-102 phase 1b melanoma study selected for oral presentation at the SITC 2022 annual meeting

September 27, 2022

Press release - Non-regulatory

Targovax receives approval to proceed with the ONCOS-102 phase 2 melanoma study from the US FDA

September 26, 2022

Press release - Non-regulatory

Reminder: Targovax to host Investor Event 27 September

September 19, 2022

Press release - Non-regulatory

Targovax to host Investor Event: Meet the Management on 27 September

September 12, 2022

Press release - Non-regulatory

Targovax to present at upcoming conferences

August 18, 2022

Press release - Regulatory

Targovax ASA: Second quarter and first half year 2022 results

August 11, 2022

Press release - Non-regulatory

Targovax ASA: Invitation to Targovax’s second quarter and first half 2022 presentation, Thursday 18 August

July 4, 2022

Press release - Regulatory

Targovax: Completion of drop-down demerger

June 23, 2022

Press release - Non-regulatory

Targovax announces that the FDA has granted authorization to initiate clinical trials with the enhanced TG01 RAS vaccine in the USA

June 23, 2022

Press release - Non-regulatory

Targovax: FDA gir tillatelse til å starte kliniske studier med ny og forbedret TG01 kreftvaksine i USA

June 7, 2022

Press release - Regulatory

Targovax ASA: Registration of share capital increase following settlement of restricted stock units and exercise of employee options

May 31, 2022

Press release - Regulatory

Targovax ASA: Mandatory notification of trade by primary insiders pertaining to RSUs

May 31, 2022

Press release - Regulatory

Targovax ASA: Exercise of options, settlement of restricted stock units and resolutions to increase the share capital

May 27, 2022

Press release - Non-regulatory

Targovax announces publication of the two abstracts accepted for poster presentation at ASCO 2022

May 12, 2022

Press release - Regulatory

Targovax ASA: First quarter 2022 results

May 11, 2022

Press release - Regulatory

Targovax announces clinical collaboration with Agenus for upcoming ONCOS-102 phase 2 melanoma trial

May 11, 2022

Press release - Non-regulatory

Targovax to present at upcoming conferences

May 10, 2022

Press release - Non-regulatory

Targovax and Oslo University Hospital announce collaboration to test TG mutant RAS vaccination in multiple myeloma

May 3, 2022

Press release - Non-regulatory

Targovax ASA: Invitation to presentation of Targovax’s first quarter 2022 results, Thursday 12 May

April 28, 2022

Press release - Non-regulatory

Targovax ASA: Two ONCOS-102 abstracts accepted for ASCO

April 26, 2022

Press release - Non-regulatory

Targovax to present at 5th Neoantigen Summit Europe in Amsterdam

April 21, 2022

Press release - Non-regulatory

Targovax ASA announces the appointment of two new Board Directors

April 20, 2022

Press release - Regulatory

Targovax ASA: Issuance of restricted stock units (RSUs) to the board members

April 20, 2022

Press release - Regulatory

Targovax ASA: Minutes from the Annual General Meeting

March 30, 2022

Press release - Regulatory

Notice of Annual General Meeting

March 14, 2022

Press release - Regulatory

Targovax – Proposal to implement a drop-down demerger

March 9, 2022

Press release - Regulatory

Targovax ASA: Annual Report 2021

March 9, 2022

Press release - Non-regulatory

Targovax ASA: Poster presentation at the AACR Annual Meeting

March 8, 2022

Press release - Regulatory

Targovax ASA: Registration of share capital increases following exercise of options

March 7, 2022

Press release - Regulatory

Targovax ASA: GRANT OF SHARE OPTIONS TO NEW CFO

March 7, 2022

Press release - Non-regulatory

Targovax ASA and Agenus announce collaboration on mutant KRAS cancer vaccine adjuvanted with QS-21 STIMULON™

March 2, 2022

Press release - Regulatory

Targovax ASA: Mandatory notification of trade by primary insider in connection with settlement of RSUs

March 2, 2022

Press release - Regulatory

Targovax ASA: Exercise of options under LTI program, settlement of RSUs and resolution to increase the share capital

February 28, 2022

Press release - Regulatory

Targovax ASA strengthens management with Lubor Gaal as Chief Financial Officer

February 17, 2022

Press release - Regulatory

Targovax ASA: Fourth quarter 2021 results

February 9, 2022

Press release - Regulatory

Targovax ASA: Invitation to presentation of Targovax’s fourth quarter 2021 results, Thursday 17 February

February 1, 2022

Press release - Non-regulatory

Targovax inngår forskningssamarbeid med Karolinska Institutet (Norwegian)

February 1, 2022

Press release - Regulatory

Targovax and Prof. Michael Uhlin at Karolinska Institutet enter research collaboration

January 17, 2022

Press release - Non-regulatory

Targovax granted Patents for ONCOS-102 in combination with chemotherapy in China and Japan

January 12, 2022

Press release - Regulatory

Targovax ASA: Targovax awarded NOK 8.2m grant by Innovation Norway